Geneva, 27 February 2019 - The International Generic and Biosimilar medicines Association (IGBA) welcomes Health Canada’s decision to proceed with a biologic naming policy that identifies all biologic medicines, including biosimilars, by their unique brand name and non-proprietary (common) name, without the addition of a product-specific suffix. Health Canada made the decision following a domestic consultation process with stakeholders.
February 22, 2019 – Toronto – The following is a statement by Jim Keon, Chair of the International Generic and Biosimilars medicines Association (IGBA), on the passing of Dilip Shah, Secretary-General of the Indian Pharmaceutical Association (IPA).
IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announces today the nomination of Suzette Kox as Secretary General of the association. Her main role is to coordinate the IGBA activities as IGBA continues to expand its outreach relevant to its mission, priorities and operations.
- IGBA Position Paper - Medicines Shortages (Reposted December 2018)
- IGBA Reflection Paper on waiving bridging studies for biosimilar medicines applications
- IGBA Position on Identification of Biological, including Biosimilar Medicines 2018 Update of Facts & Figures
- IGBA submission to HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs [RIN 0991-ZA49]
